Philip Morris stated it expects to document a loss on the sale of its inhaled-therapeutics unit to Molex Asia Holdings because it retools its pharmaceutical enterprise.
in Business
Philip Morris to Take $220 Million Loss on Sale of Inhaled-Medicine Unit
